Data / Form D filings / NX Pharmagen Inc.
NX Pharmagen Inc.: Form D filings
NX Pharmagen Inc., a biotechnology company in Louisville, KY, filed 4 Form D notices with the SEC between 2010 and 2022. The latest, on October 21, 2022, reports $590,000 sold of a $1 million offering to 19 investors.
Find out what NX Pharmagen Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 4350 BROWNSBORO ROAD, SUITE 110, Louisville, KY, 40207
- Phone
- (502) 893-4570
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1508691
The full lists. Form D filings in Kentucky: 216 rows, $10.80, or the new rows each week for $19 a month. Form D filings in Biotechnology: 1,568 rows, $78.40, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Oct 21, 2022 | New notice | $1,000,000 | $590,000 | $410,000 | 19 | Oct 10, 2022 | sec.gov |
| Aug 31, 2020 | New notice | $1,000,000 | $486,000 | $514,000 | 13 | Aug 17, 2020 | sec.gov |
| Jun 25, 2013 | New notice | $1,000,000 | $773,000 | $227,000 | 0 | Jun 24, 2013 | sec.gov |
| Dec 28, 2010 | New notice | $1,500,000 | $0 | $1,500,000 | 0 | Yet to occur | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Alan Ezrin | Director | |
| Brian Brohman | Executive Officer, Director | |
| Robert Saunders | Director |
Every Form D from the week of Oct 17, 2022 · All recent filings in Kentucky · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what NX Pharmagen Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.